Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $23.00

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) has earned a consensus recommendation of "Buy" from the seven research firms that are covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $23.00.

A number of brokerages have recently commented on AURA. Cowen restated a "buy" rating on shares of Aura Biosciences in a research note on Friday, October 18th. Lifesci Capital raised shares of Aura Biosciences to a "strong-buy" rating in a research note on Monday, September 9th. HC Wainwright reiterated a "buy" rating and issued a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th. JMP Securities raised their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a "market outperform" rating in a research report on Friday, September 13th. Finally, Evercore ISI upgraded shares of Aura Biosciences to a "strong-buy" rating in a research report on Monday, September 16th.

Aura Biosciences Trading Up 1.1 %

NASDAQ AURA traded up $0.09 on Wednesday, hitting $8.22. 114,533 shares of the company's stock traded hands, compared to its average volume of 180,960. The firm has a market capitalization of $410.60 million, a PE ratio of -4.75 and a beta of 0.26. Aura Biosciences has a 1-year low of $6.63 and a 1-year high of $12.38. The firm's 50-day moving average price is $9.29 and its two-hundred day moving average price is $8.83.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.02. On average, research analysts anticipate that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.

Insider Activity

In other Aura Biosciences news, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.36, for a total transaction of $110,653.92. Following the sale, the insider now owns 151,693 shares of the company's stock, valued at $1,419,846.48. The trade was a 7.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CTO Mark Plavsic sold 7,383 shares of the company's stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now directly owns 121,132 shares of the company's stock, valued at $1,193,150.20. The trade was a 5.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 79,081 shares of company stock worth $891,353 over the last 90 days. 5.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aura Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. American Century Companies Inc. acquired a new stake in Aura Biosciences in the 2nd quarter valued at about $119,000. SG Americas Securities LLC acquired a new stake in shares of Aura Biosciences in the third quarter valued at approximately $169,000. JPMorgan Chase & Co. lifted its position in Aura Biosciences by 107.5% during the third quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company's stock worth $477,000 after buying an additional 27,718 shares in the last quarter. Barclays PLC lifted its position in Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company's stock worth $544,000 after buying an additional 43,897 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company's stock worth $480,000 after buying an additional 18,011 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.